Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of NeoGenomics, Inc. (NASDAQ: NEO) between August 6, 2021 and March 28, 2022.
NeoGenomics investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.
NeoGenomics operates a network of cancer-focused testing laboratories and provides testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
On March 28, 2022, NeoGenomics announced the resignation of its Chief Executive Officer, Mark Mallon, and revealed that its first-quarter financials will miss guidance and that the company would be rescinding its forecast for the full year.
Following this news, NeoGenomics’ stock price fell by $5.30 per share, or approximately 29.8%, to close at $12.49 per share on March 29, 2022.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.